Wegovy vs Saxenda compared: weekly semaglutide vs daily liraglutide, the STEP 8 head-to-head results, side effects, Saxenda's 2027 discontinuation and dated prices. No winner declared.
Fact-checked against FDA labels and official sources; not yet reviewed by a licensed clinician. This page is education, not medical advice. Talk to your doctor before starting, stopping or changing any treatment.
Key takeaways
- Wegovy (semaglutide) and Saxenda (liraglutide) are both GLP-1 medicines FDA approved for chronic weight management in adults and in teens 12 and older with obesity.[2]
- In the STEP 8 head-to-head trial, average weight change at 68 weeks was -15.8% with weekly semaglutide and -6.4% with daily liraglutide.[3]
- Wegovy is injected weekly or taken as a daily pill and also has a cardiovascular and a MASH indication; Saxenda is a daily injection for weight management only.[1]
- Novo Nordisk is discontinuing Saxenda, with last shipments to wholesalers in late January 2027; generic liraglutide was approved in August 2025.[8]
- Both carry a boxed warning about thyroid C-cell tumors in rodents and mostly cause digestive side effects.[1]
The short answer
Both are Novo Nordisk GLP-1 medicines FDA approved for chronic weight management in adults with obesity, or overweight with a weight-related condition, and in teens 12 and older with obesity. Wegovy (semaglutide) is injected weekly or taken as a daily pill; Saxenda (liraglutide) is injected daily. In the STEP 8 head-to-head trial, average weight loss was larger with semaglutide. Saxenda is being discontinued, with last shipments in late January 2027.
Scorecards
| Wegovy (semaglutide): uses, side effects, cost and FDA statusFDA approved for weight managementPrescriptionInjection | Saxenda (liraglutide 3 mg): uses, side effects and costFDA approved for weight managementPrescriptionInjection | |
|---|---|---|
| Medical supervision | Required | Required |
No overall score and no winner: what matters depends on you. Hover a value for its definition.
Facts side by side
| Wegovy (semaglutide): uses, side effects, cost and FDA statusFDA approved for weight managementPrescriptionInjection | Saxenda (liraglutide 3 mg): uses, side effects and costFDA approved for weight managementPrescriptionInjection | |
|---|---|---|
| Purpose | Reduce excess body weight and maintain weight reduction long term (with reduced-calorie diet and increased physical activity); Reduce excess body weight and maintain weight reduction long term (injection); Reduce the risk of major adverse cardiovascular events (CV death, nonfatal heart attack, nonfatal stroke); Noncirrhotic MASH with moderate to advanced liver fibrosis (F2 to F3), accelerated approval (injection); Weight reduction and maintenance, and cardiovascular risk reduction (Wegovy tablets) | Reduce excess body weight and maintain weight reduction long term, with a reduced-calorie diet and increased physical activity; Reduce excess body weight and maintain weight reduction long term |
| Class or type | GLP-1 receptor agonist | GLP-1 receptor agonist |
| Regulatory status | FDA approved for weight managementPrescriptionInjection | FDA approved for weight managementPrescriptionInjection |
| Prescription required | Yes | Yes |
| How it works | Wegovy (semaglutide): FDA-approved uses, who the label covers, how it is taken in general, trial results, side effects, boxed warning and dated prices. | Saxenda (liraglutide 3 mg): FDA-approved uses for adults and teens, the daily routine in general, trial results, side effects, boxed warning, cost and the 2027 brand discontinuation. |
| How it is done or taken | Injection | Injection |
| How often | Weekly | Daily |
| Average outcomes in studies |
|
|
| Main risks |
|
|
| Cost (dated) | from 25 USD per month with commercial coverage (max savings $100 a month; government beneficiaries excluded) (checked October 6, 2026) | from 738.72 USD NADAC pharmacy acquisition cost, generic liraglutide 5-pen pack, 15 mL (rate effective 2026-09-23) (checked October 6, 2026) |
| Official resources | dailymed.nlm.nih.gov | dailymed.nlm.nih.gov |
What the trials showed
- STEP 8 (NCT04074161) 338 adults with overweight or obesity, no diabetes, 68 weeks, open label between active drugs: weight change -15.8% with semaglutide 2.4 mg weekly vs -6.4% with liraglutide 3.0 mg daily (pooled placebo -1.9%); 10% or more lost by 70.9% vs 25.6%; discontinuation for any reason 13.5% vs 27.6%; GI adverse events 84.1% vs 82.7%.[3]
Side effects compared
| Wegovy (semaglutide): uses, side effects, cost and FDA statusFDA approved for weight managementPrescriptionInjection | Saxenda (liraglutide 3 mg): uses, side effects and costFDA approved for weight managementPrescriptionInjection | |
|---|---|---|
| From the label |
|
|
Cost and coverage
| Option | Price | Amount | Basis | Checked on |
|---|---|---|---|---|
| Wegovy (semaglutide): uses, side effects, cost and FDA status | List price | 1,349.02 USD | per package (pen, HD pen or pill) | October 6, 2026 |
| Wegovy (semaglutide): uses, side effects, cost and FDA status | Self-pay / cash | 349 USD | per month, pens 0.25 mg to 2.4 mg, NovoCare Pharmacy | October 6, 2026 |
| Wegovy (semaglutide): uses, side effects, cost and FDA status | Self-pay / cash | 399 USD | per month, Wegovy HD 7.2 mg pen, NovoCare Pharmacy | October 6, 2026 |
| Wegovy (semaglutide): uses, side effects, cost and FDA status | Self-pay / cash | 199 USD | per month, first 2 fills of 0.25 mg and 0.5 mg for new patients, through 2026-12-31 | October 6, 2026 |
| Wegovy (semaglutide): uses, side effects, cost and FDA status | With savings program | 25 USD | per month with commercial coverage (max savings $100 a month; government beneficiaries excluded) | October 6, 2026 |
| Saxenda (liraglutide 3 mg): uses, side effects and cost | List price | 1,349.02 USD | WAC per 5-pen package (5 x 3 mL), about 30 days at 3 mg | October 6, 2026 |
| Saxenda (liraglutide 3 mg): uses, side effects and cost | Other | 1,306.89 USD | NADAC pharmacy acquisition cost, Saxenda 15 mL (rate effective 2026-09-23) | October 6, 2026 |
| Saxenda (liraglutide 3 mg): uses, side effects and cost | Other | 738.72 USD | NADAC pharmacy acquisition cost, generic liraglutide 5-pen pack, 15 mL (rate effective 2026-09-23) | October 6, 2026 |
Prices change often and depend on pharmacy, plan and location. Insurance can change what you pay. Every price shows the date we checked it.
Things people weigh up
- Schedule: Wegovy is a weekly injection or a daily tablet; Saxenda is a daily injection with a new needle each time.
- Average weight loss in STEP 8 was larger with semaglutide (15.8% vs 6.4%); individual responses vary widely.
- Other approved uses: Wegovy is also approved to lower cardiovascular risk in adults with heart disease and for MASH; Saxenda is approved for weight management only.
- Availability: Saxenda is being discontinued (last shipments late January 2027); generic liraglutide was approved in August 2025.
- Cost: Wegovy has a manufacturer self-pay price and a savings offer; Medicare's GLP-1 Bridge includes Wegovy but not Saxenda.
- Side effects are similar in kind (mostly digestive); tolerability differs from person to person.
- Teens: both are approved for ages 12 and older with obesity; Saxenda also requires a body weight above 60 kg.
These are the differences people commonly consider, not a recommendation. A clinician can help you decide what fits you.
In short: Wegovy (semaglutide) and Saxenda (liraglutide) are both GLP-1 medicines from Novo Nordisk that are FDA approved for chronic weight management in adults with obesity, or overweight with a weight-related condition, and in teens 12 and older with obesity. The biggest practical difference is how often they are injected: Wegovy once a week (it also comes as a daily pill), Saxenda once a day. In the one head-to-head trial, STEP 8, average weight loss at 68 weeks was 15.8% with semaglutide and 6.4% with liraglutide. Novo Nordisk is discontinuing Saxenda, with last shipments to wholesalers in late January 2027 (checked on October 6, 2026).
This page puts the facts side by side so you can have a better conversation with a licensed clinician. It does not say which medicine is right for anyone: that depends on your health history, other medicines, preferences, coverage and a proper medical evaluation. InstaTuck does not sell or prescribe either medicine.
Wegovy vs Saxenda at a glance
- -15.8% vs -6.4%average weight change at 68 weeks, semaglutide vs liraglutide (STEP 8 head-to-head)JAMA 2022
- Weekly vs dailyhow often each injection is given (Wegovy also comes as a daily tablet)FDA labels
- Late Jan 2027Saxenda's last shipments to wholesalers before it is discontinuedNovoCare
Checked on October 6, 2026
The basics side by side
| Wegovy | Saxenda | |
|---|---|---|
| Active ingredient | Semaglutide | Liraglutide |
| Drug class | GLP-1 receptor agonist | GLP-1 receptor agonist |
| Maker | Novo Nordisk | Novo Nordisk |
| How it is taken | Injection under the skin once a week; also a once-daily tablet (the Wegovy pill) | Injection under the skin once a day |
| First FDA approval for weight | June 4, 2021 | December 23, 2014 |
| Weight-management population (label) | Adults with obesity, or overweight with at least one weight-related condition; teens 12 and older with obesity (injection) | Adults with obesity, or overweight with at least one weight-related condition; teens 12 and older weighing more than 60 kg (132 lb) with obesity |
| Other approved uses | Lower risk of heart attack, stroke and cardiovascular death in adults with heart disease and obesity or overweight; MASH (a fatty-liver disease) with moderate to advanced fibrosis (injection) | None beyond weight management |
| Boxed warning | Thyroid C-cell tumors in rodents | Thyroid C-cell tumors in rodents |
| Generic available | No | Yes: generic liraglutide was approved in August 2025 |
| Status | Marketed | Being discontinued; last shipments to wholesalers in late January 2027 |
How they work, and why the schedules differ
Both medicines copy GLP-1, a gut hormone that the body releases after eating. GLP-1 receptor agonists act on the brain’s appetite centers and slow the emptying of the stomach, so people tend to feel full sooner and eat less. Our guide to GLP-1 medications explains the mechanism in more detail, and the generic pages for semaglutide and liraglutide cover each molecule across its brands.
The two molecules differ mainly in how long they stay in the body. Semaglutide was designed to last about a week, which is why Wegovy is a weekly injection. Liraglutide is cleared faster, so Saxenda is injected every day. Both labels describe a gradual dose increase at the start to help the stomach adjust: Saxenda steps up each week over about five weeks, while Wegovy’s injection steps up every four weeks over about four months. Your prescriber sets the schedule; never change a dose on your own.
What the head-to-head trial showed (STEP 8)
STEP 8 is the only randomized trial that compared the two directly. It enrolled 338 adults without diabetes who had a BMI of 30 or more, or 27 or more with a weight-related condition, at 19 U.S. sites. People received weekly semaglutide 2.4 mg, daily liraglutide 3.0 mg or a matching placebo for 68 weeks, all with diet and physical-activity counseling. The comparison between the two active medicines was open label, meaning participants knew which one they were taking, and the trial was funded by Novo Nordisk, which makes both.
| Item | Value |
|---|---|
| Semaglutide 2.4 mg weekly (Wegovy dose) | 15.8% |
| Liraglutide 3.0 mg daily (Saxenda dose) | 6.4% |
| Placebo (pooled) | 1.9% |
Percent of starting body weight. Open-label comparison of the two active drugs; funded by Novo Nordisk.
Source: Rubino DM et al., JAMA 2022 (STEP 8, 338 adults) (checked on October 6, 2026)
The difference was 9.4 percentage points. More people on semaglutide also reached the larger milestones, as the chart below shows. Treatment was stopped for any reason by 13.5% of people on semaglutide and 27.6% on liraglutide. Digestive side effects were reported by about the same share in both groups: 84.1% and 82.7%.
| Item | Semaglutide | Liraglutide |
|---|---|---|
| Lost 10% or more | 70.9% | 25.6% |
| Lost 15% or more | 55.6% | 12% |
| Lost 20% or more | 38.5% | 6% |
Averages and shares from one 68-week trial; individual results vary widely.
Source: Rubino DM et al., JAMA 2022 (STEP 8) (checked on October 6, 2026)
What the placebo-controlled trials showed
Each medicine also has its own larger trials against placebo. In STEP 1, adults without diabetes on semaglutide 2.4 mg lost an average of 14.9% of their weight at 68 weeks, compared with 2.4% on placebo. In Saxenda’s main trial (Study 1 on the label, 56 weeks, adults without diabetes), average weight change was -7.4% versus -3.0% on placebo, and 62.3% versus 34.4% lost at least 5%. These were different trials, years apart, with different people, so the head-to-head result above is the fairer comparison.
| Item | Medicine | Placebo |
|---|---|---|
| Wegovy (STEP 1, 68 weeks) | 14.9% | 2.4% |
| Saxenda (label Study 1, 56 weeks) | 7.4% | 3% |
Separate trials with different lengths and populations; not a direct comparison. Saxenda figures from the DailyMed label.
Source: Wilding JPH et al., NEJM 2021 (STEP 1); Saxenda prescribing information, Table 4 (checked on October 6, 2026)
Beyond weight, semaglutide has a dedicated heart-outcomes trial in people with obesity: in SELECT, major cardiovascular events occurred in 6.5% of people on semaglutide and 8.0% on placebo. That trial is the basis for Wegovy’s heart-risk indication. Saxenda does not carry a cardiovascular indication. In a three-year Saxenda study of adults with prediabetes, 2% of people on liraglutide and 6% on placebo were diagnosed with type 2 diabetes, but preventing diabetes is not an approved use.
Side effects compared
The two labels report rates from their own trials, so the numbers are not a direct comparison. They show the same pattern: digestive effects are the most common, mostly mild to moderate, and most frequent while the dose is being increased.
| Item | Wegovy 2.4 mg | Saxenda 3 mg |
|---|---|---|
| Nausea | 44% | 39.3% |
| Diarrhea | 30% | 20.9% |
| Vomiting | 24% | 15.7% |
| Constipation | 24% | 19.4% |
Placebo rates: Wegovy trials 16/16/6/11%; Saxenda trials 13.8/9.9/3.9/8.5%. Different trials, so not a head-to-head comparison.
Source: Wegovy and Saxenda prescribing information (DailyMed), adverse reaction tables (checked on October 6, 2026)
| Label fact | Wegovy | Saxenda |
|---|---|---|
| Stopped because of side effects (adult trials) | 6.8% vs 3.2% on placebo (2.4 mg injection) | 9.8% vs 4.3% on placebo |
| Injection-site reactions | Listed on the label | 13.9% vs 10.5% on placebo |
| Low blood sugar | Higher risk with insulin or sulfonylureas | 12.6% vs 6.6% in adults with type 2 diabetes; higher risk with insulin or sulfonylureas |
| Gallstones | Listed under gallbladder disease | 2.2% vs 0.8% on placebo |
| Heart rate | Increase listed as a warning | Average increase of 2 to 3 beats per minute; increase of more than 10 bpm in 34% vs 19% |
The serious warnings overlap almost completely because the medicines are in the same class: a boxed warning about thyroid C-cell tumors seen in rodents (neither is used by people with a personal or family history of medullary thyroid carcinoma or MEN 2), pancreatitis, gallbladder disease, low blood sugar when combined with insulin or sulfonylureas, kidney problems from dehydration, allergic reactions, a faster heart rate and the risk of breathing in stomach contents during anesthesia or deep sedation. Wegovy’s label also covers diabetic eye complications in people with type 2 diabetes. Neither is used during pregnancy for weight loss. Read the full lists on Wegovy side effects and in our GLP-1 side effects guide.
Daily or weekly: the practical differences
- Injections per month. About 30 with Saxenda and 4 with the Wegovy pen. Some people prefer a weekly routine; others like a daily habit. The Wegovy pill is a daily tablet taken on an empty stomach with a small sip of water, 30 minutes before food or other medicines.
- Needles. Saxenda is a multi-dose pen, and its label says to remove the needle after each injection, so a new needle is used every day. The Wegovy pen is a single-dose pen: one pen per weekly dose.
- Checking whether it is working. Saxenda’s label tells prescribers to evaluate weight at 16 weeks and stop if a person has not lost at least 4% of their starting weight, because they are unlikely to benefit. Your clinician will have their own plan for check-ins with either medicine.
- Missed doses. Each label has its own rules; with Saxenda, if more than three days are missed, the label says to restart at the lowest dose. Ask your prescriber what to do before it happens.
- Storage. Both pens are refrigerated before first use. Your pharmacist can explain the room-temperature limits for each.
Saxenda is being discontinued: what that means
Novo Nordisk says it will discontinue the Saxenda brand, with last shipments to wholesalers in late January 2027. The company says the reason is that alternative medicines have become available and fewer patients use Saxenda, not a safety or quality problem. The Saxenda savings offer closed to new enrollees on June 30, 2023. Generic liraglutide 3 mg (18 mg/3 mL pens) referencing Saxenda was approved by the FDA on August 27, 2025, so liraglutide itself may stay available from some pharmacies. If you use Saxenda today, ask your prescriber now about a plan for 2027, whether that is generic liraglutide, another medicine or a non-drug path.
Cost and coverage (checked on October 6, 2026)
Wegovy and Saxenda have the same list price per package, $1,349.02 (Saxenda’s 5-pen package, as listed by Novo Nordisk in February 2025), but what people actually pay differs a lot. Wegovy has a manufacturer self-pay price through NovoCare Pharmacy; we found no current manufacturer self-pay price for Saxenda.
- With commercial insurance that covers Wegovy: Novo Nordisk’s savings offer lets eligible people pay as little as $25 a month (maximum savings $100 a month); government beneficiaries are excluded.
- Medicare: the temporary Medicare GLP-1 Bridge (July 1, 2026 to December 31, 2027) covers Wegovy injection and tablets for weight management with a $50 copay for people who meet its criteria and get prior authorization. Saxenda is not on the Bridge list.
- Generic liraglutide: prices vary by pharmacy and plan; we did not find a manufacturer price to quote.
More detail: Wegovy cost and savings, does insurance cover GLP-1s? and the dated prices in our GLP-1 cost comparison tool.
Stopping, and keeping weight off
Weight usually comes back when GLP-1 medicines stop. In STEP 4, people who switched from semaglutide to placebo after 20 weeks regained 6.9% of their weight over the next 48 weeks, while those who stayed on it lost a further 7.9%. Planning for the long term, including protein, strength training and follow-up, matters with either medicine; see life after a GLP-1 and muscle loss on GLP-1s.
Other options to ask about
Other FDA-approved choices include Zepbound (tirzepatide, weekly; compared in Wegovy vs Zepbound), the daily pill Foundayo (see Wegovy vs Foundayo) and non-GLP-1 pills such as Qsymia and Contrave. Compounded semaglutide or liraglutide is not FDA approved; our page on compounded GLP-1s explains why. The full list is on the weight-loss medications hub, and Find My Options can help you see which categories to research.
Compared with the items
FDA approved for weight managementPrescriptionInjectionWegovy (semaglutide): uses, side effects, cost and FDA statusSemaglutide: one ingredient, several brands · Injection · Weekly
FDA approved for weight managementPrescriptionInjectionSaxenda (liraglutide 3 mg): uses, side effects and costLiraglutide: the daily GLP-1 (Saxenda, Victoza) and generics · Injection · DailyRelated comparisons
Related guides
GLP-1 Medications: how they work and which are approved for weightGLP-1 medications explained: what GLP-1 is, how the drugs work, which brands are FDA approved for…
GLP-1 Side Effects: common, serious and how they are managedGLP-1 side effects from the FDA labels: common digestive effects by brand, serious risks, the thyroid…
Stopping a GLP-1: regain, what trials show and keeping resultsWhat happens when you stop a GLP-1: STEP 1 extension, STEP 4, SURMOUNT-4 and BMJ meta-analysis…
Wegovy Cost, Coupons and Savings Programs (prices checked monthly)What Wegovy costs, with dates: list price, NovoCare self-pay prices for pens and pills, the $25…Tools for this topic
Questions to ask a professional
- Given my health history, is a weekly or a daily medicine a better fit for me?
- If I am on Saxenda now, what is our plan before it is discontinued in 2027?
- Do I have heart disease or another condition that makes Wegovy's other approved uses relevant?
- What does my insurance cover, and would generic liraglutide cost me less?
- Which side effects should we watch for, and when should I call you?
- How will we protect muscle and plan for the long term if I stop?
Frequently asked questions
Which works better, Wegovy or Saxenda?
In STEP 8, the only head-to-head trial, average weight loss at 68 weeks was 15.8% with semaglutide (the Wegovy dose) and 6.4% with liraglutide (the Saxenda dose). Averages do not predict any one person's result, and side effects, schedule, coverage and other conditions also matter. A clinician can help weigh them for you.
Is Saxenda being discontinued?
Yes. Novo Nordisk says it is discontinuing Saxenda, with last shipments to wholesalers in late January 2027, because of alternatives and declining use, not safety. Generic liraglutide was approved by the FDA in August 2025.
Can I switch from Saxenda to Wegovy?
Switching is a prescriber decision. Both labels say not to use them together or with other GLP-1 medicines, and a new medicine is usually started according to its own label. Ask your prescriber how to time the change.
Are the side effects different?
They are similar in kind: nausea, diarrhea, vomiting and constipation are the most common with both, mostly early on. In STEP 8, digestive side effects were reported by 84.1% on semaglutide and 82.7% on liraglutide.
Is Saxenda the same as Victoza?
Both contain liraglutide, but Victoza is a diabetes medicine at lower doses. Saxenda's label says doses below 3 mg are not established for weight management and that the two should not be used together.
Which one costs less?
Both list at $1,349.02 per package. On 2026-10-06, Wegovy self-pay through NovoCare Pharmacy was $349 a month for most pen strengths and $149 to $299 for pills; we found no manufacturer self-pay price for Saxenda. Generic liraglutide prices vary by pharmacy.
Does Medicare cover Wegovy or Saxenda for weight loss?
The temporary Medicare GLP-1 Bridge (July 1, 2026 to December 31, 2027) covers Wegovy for weight management with a $50 copay for people who meet its criteria. Saxenda is not on the Bridge list.
Can teenagers use them?
Both are FDA approved for teens 12 and older with obesity; Saxenda also requires a body weight above 60 kg (132 lb). Decisions for teens belong with a pediatric clinician.
What happens if I stop?
Weight tends to return after stopping. In STEP 4, people switched from semaglutide to placebo regained 6.9% over 48 weeks. Plan stopping with your prescriber.
References
- WEGOVY (semaglutide) injection and tablets: prescribing information. Novo Nordisk, via DailyMed, 2026. (accessed October 7, 2026) Drug label
- SAXENDA (liraglutide) injection: prescribing information. Novo Nordisk, via DailyMed, 2026. (accessed October 6, 2026) Drug label
- Rubino DM, Greenway FL, Khalid U, et al.. Effect of Weekly Subcutaneous Semaglutide vs Daily Liraglutide on Body Weight (STEP 8). JAMA, 2022. doi:10.1001/jama.2021.23619 · PMID 35015037 · NCT04074161 (accessed October 6, 2026) Randomized trial
- Wilding JPH, Batterham RL, Calanna S, et al.. Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1). New England Journal of Medicine, 2021. doi:10.1056/NEJMoa2032183 · PMID 33567185 · NCT03548935 (accessed October 7, 2026) Randomized trial
- Lincoff AM, Brown-Frandsen K, Colhoun HM, et al.. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes (SELECT). New England Journal of Medicine, 2023. doi:10.1056/NEJMoa2307563 · PMID 37952131 · NCT03574597 (accessed October 7, 2026) Randomized trial
- le Roux CW, Astrup A, Fujioka K, et al.. 3 years of liraglutide versus placebo for type 2 diabetes risk reduction and weight management in individuals with prediabetes. The Lancet, 2017. doi:10.1016/S0140-6736(17)30069-7 · PMID 28237263 (accessed October 6, 2026) Randomized trial
- Rubino D, Abrahamsson N, Davies M, et al.. Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance (STEP 4). JAMA, 2021. doi:10.1001/jama.2021.3224 · PMID 33755728 · NCT03548987 (accessed October 7, 2026) Randomized trial
- Saxenda: cost information and discontinuation notice. Novo Nordisk (NovoCare). (accessed October 6, 2026) Other
- Drugs@FDA: liraglutide (Teva), ANDA 214568. U.S. Food and Drug Administration. (accessed October 6, 2026) Government page
- Drugs@FDA: Saxenda, NDA 206321 (original approval 2014-12-23). U.S. Food and Drug Administration. (accessed October 7, 2026) Government page
- Saxenda pricing (wholesale acquisition cost). Novo Nordisk. (accessed October 6, 2026) Other
- Wegovy at NovoCare Pharmacy: self-pay prices. Novo Nordisk (NovoCare Pharmacy). (accessed October 7, 2026) Other
- Wegovy cost, coverage and savings resources. Novo Nordisk (NovoCare). (accessed October 6, 2026) Other
- Medicare GLP-1 Bridge: information for providers. Centers for Medicare and Medicaid Services. (accessed October 7, 2026) Government page
Facts checked on October 6, 2026
Educational information, not medical advice. Talk with a qualified healthcare professional about your own situation. In an emergency call 911.